RALEIGH, N.C., Nov. 16, 2017 /PRNewswire/ -- BioDelivery
Sciences International, Inc. (NASDAQ: BDSI), a specialty
pharmaceutical company with a focus in pain management and
addiction medicine, today announced that Dr. Mark A. Sirgo, Vice Chairman, President and
Chief Executive Officer, will present at the 29th Annual
Piper Jaffray Conference, taking place November 28-29, 2017 in New York City.
Presentation Details:
Date:
|
Tuesday, November 28,
2017
|
Time:
|
3:00 PM Eastern
Time
|
Location:
|
Lotte New York Palace
Hotel, New York, NY
|
Dr. Sirgo will focus on progress with commercialization efforts
and strategic initiatives supporting BELBUCA®
(buprenorphine) buccal film (CIII) and BUNAVAIL®
(buprenorphine and naloxone) buccal film (CIII). As reported
in BDSI's third quarter 2017 financial results conference call,
BELBUCA sales grew 15% over the second quarter and reached all-time
weekly and monthly prescription highs in October. Dr. Sirgo
will discuss the strategy in place to continue to drive BELBUCA
sales growth and will review new managed care coverage, including
new Medicare contracts, that will become effective January 1.
Additionally, the presentation will overview ongoing efforts to
work with government agencies and legislators to highlight the
benefits of BELBUCA and bring about potential changes that could
allow BELBUCA to play a greater role as part of the solution to the
opioid crisis.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a
specialty pharmaceutical company with a focus in the areas of pain
management and addiction medicine. BDSI is utilizing its
novel and proprietary BioErodible MucoAdhesive (BEMA®)
technology and other drug delivery technologies to develop and
commercialize, either on its own or in partnership with third
parties, new applications of proven therapies aimed at addressing
important unmet medical needs.
BDSI's marketed products and those in development address
serious and debilitating conditions such as breakthrough cancer
pain, chronic pain and opioid dependence. BDSI's headquarters
is in Raleigh, North Carolina.
For more information, please visit or follow us:
Internet:
|
www.bdsi.com
|
Facebook:
|
Facebook.com/BioDeliverySI
|
Twitter:
|
@BioDeliverySI
|
BUNAVAIL® (buprenorphine and naloxone) buccal film
(CIII) and BELBUCA® (buprenorphine) buccal film (CIII)
are marketed in the U.S. by BioDelivery Sciences.
ONSOLIS® (fentanyl buccal soluble film) (CII) is
licensed in the U.S. to Collegium Pharmaceutical pursuant to the
U.S. licensing and development agreement between BDSI and
Collegium. For full prescribing information and important safety
information on BDSI products, including BOXED WARNINGS for ONSOLIS,
please visit www.bdsi.com where the Company promptly
posts press releases, SEC filings and other important information
or contact the Company at (800) 469-0261. For full
prescribing and safety information on BELBUCA, please visit
www.belbuca.com and for full prescribing and safety
information on BUNAVAIL, please visit www.bunavail.com.
Cautionary Note on Forward-Looking Statements
This press release, the presentations described herein, and any
statements of employees, representatives and partners of
BioDelivery Sciences International, Inc. (the "Company") related
thereto contain, or may contain, among other things, certain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such
forward-looking statements involve significant risks and
uncertainties. Such statements may include, without
limitation, statements with respect to the Company's plans,
objectives, projections, expectations and intentions and other
statements identified by words such as "projects," "may," "will,"
"could," "would," "should," "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "potential" or similar
expressions. These statements are based upon the current
beliefs and expectations of the Company's management and are
subject to significant risks and uncertainties, including those
detailed in the Company's filings with the Securities and Exchange
Commission. Actual results (including, without limitation,
the results of the Company's commercialization programs for
BELBUCA, BUNAVAIL and ONSOLIS) may differ significantly from those
set forth or implied in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company's control). The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or
otherwise, except as required by applicable law.
BDSI®, BEMA®, ONSOLIS®,
BUNAVAIL® and BELBUCA® are registered
trademarks of BioDelivery Sciences International, Inc. The
BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks
owned by BioDelivery Sciences International, Inc. All other
trademarks and tradenames are owned by their respective owners.
© 2017 BioDelivery Sciences International, Inc. All rights
reserved.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biodelivery-sciences-to-present-at-the-29th-annual-piper-jaffray-conference-300557509.html
SOURCE BioDelivery Sciences International, Inc.